Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine

The goal is to compare the quality of post-cesarean analgesia, the side effects and the incidence of residual scar pain obtained with intrathecal morphine (reference treatment) or with a continuous intra-wound solution including both ropivacain and diclofenac (experimental treatment).

Inclusion Criteria: * single, normally progressing pregancy * term \> 36 weeks amenorrhea * BMI between 20 and 25 kg/m\^2 before pregnancy * height between 55 and 90 kg * cesarean section by Joel-Cohen or Pfannenstiel techniques * patient has signed consent * patient has social security coverage Exclusion Criteria: * Multiple pregnancy * pathological pregnancy: hypertension (\>140/90 mmHg found during the pregnancy), pre-eclampsia, gestational diabetes * term \< 36 weeks amenorrhea * non-pregnancy related maternal pathology (insufficiency) * obesity (BMI \> 25 kg/m\^2 before pregnancy) * height \< 155 cm or \> 180 cm * weight \< 55 kg or \> 90 kg * patient refuses to sign consent * surgical technique other than Joel-Cohen or Pfannenstiel * hepatic insufficiency (prothrombin \< 60%) * contra-indications for rachianesthesia: infection, hemostasis problems (platelets \< 80.109/L, prothrombin \< 60%, TCA \> 40s) * allergy to local anesthestics * patient is participating in another study, or has participated in another study within the last 6 months * patient is under any type of guardianship